BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 34508829)

  • 21. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.
    Lin M; Zheng X; Yan J; Huang F; Chen Y; Ding R; Wan J; Zhang L; Wang C; Pan J; Cao X; Fu K; Lou Y; Feng XH; Ji J; Zhao B; Lan F; Shen L; He X; Qiu Y; Jin J
    Nat Commun; 2024 Jun; 15(1):4995. PubMed ID: 38862474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
    Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
    Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
    [No Abstract]   [Full Text] [Related]  

  • 23. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
    Xia H; Dai X; Yu H; Zhou S; Fan Z; Wei G; Tang Q; Gong Q; Bi F
    Cell Death Dis; 2018 Feb; 9(3):269. PubMed ID: 29449645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma.
    Zhang C; Wei W; Tu S; Liang B; Li C; Li Y; Luo W; Wu Y; Dai X; Wang Y; Zheng L; Hao L; Zhang C; Luo Z; Chen YG; Yan X
    J Biol Chem; 2024 Apr; 300(4):107208. PubMed ID: 38521502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.
    Liu P; Zhang H; Liang X; Ma H; Luan F; Wang B; Bai F; Gao L; Ma C
    Oncotarget; 2015 Oct; 6(30):29048-59. PubMed ID: 26315112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.
    Han SX; Bai E; Jin GH; He CC; Guo XJ; Wang LJ; Li M; Ying X; Zhu Q
    J Immunol Res; 2014; 2014():261365. PubMed ID: 24860833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wogonin Induces Cell Cycle Arrest and Apoptosis of Hepatocellular Carcinoma Cells by Activating Hippo Signaling.
    Wu K; Teng M; Zhou W; Lu F; Zhou Y; Zeng J; Yang J; Liu X; Zhang Y; Ding Y; Shen W
    Anticancer Agents Med Chem; 2022; 22(8):1551-1560. PubMed ID: 34431466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fingolimod exerts
    Du J; Qian M; Yuan T; Zhang B; Chen X; An N; He Q; Yang B; Ye S; Zhu H
    Acta Pharm; 2022 Sep; 72(3):427-436. PubMed ID: 36651547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
    Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
    Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
    Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
    Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma.
    Higashi T; Hayashi H; Kitano Y; Yamamura K; Kaida T; Arima K; Taki K; Nakagawa S; Okabe H; Nitta H; Imai K; Hashimoto D; Chikamoto A; Beppu T; Baba H
    Med Oncol; 2016 Nov; 33(11):123. PubMed ID: 27734263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
    Sun T; Mao W; Peng H; Wang Q; Jiao L
    Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.
    Wang D; Li Z; Li X; Yan C; Yang H; Zhuang T; Wang X; Zang Y; Liu Z; Wang T; Jiang R; Su P; Zhu J; Ding Y
    J Exp Clin Cancer Res; 2022 Jul; 41(1):219. PubMed ID: 35820928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.